Fritextsökning
Innehållstyper
-
Instrument för snabb homogenisering av prover
Fastprep-serien av instrument ska leverera homogenisering, malning och lysering med hög provgenomströmning samtidigt som krav på kvalitet och reproducerbarhet bibehålls.
-
New firm based on SLU research
Four researchers at the Swedish University of Agricultural Sciences, SLU, has recently founded a new nanotech company.
-
Fewer visitors but satisfied exhibitors
Biotech Forum Scanlab attracted fewer visitors than in 2008. Exhibition manager Bo Rasmussen is content, claiming that the exhibitors are very satisfied.
-
Apoteket gets new vice CEO
The Swedish government company Apoteket has recently appointed a vice CEO.
-
Samarbete med universitet ska gynna Novo
I Combine samarbetar sex svenska universitet för att skapa bättre förståelse kring inflammatoriska sjukdomar. Bolaget ska nu delta i ett projekt för att arbeta ...
-
Orexo opens doors eastwards
The drug delivery company has signed a deal for selling a cancer pain treatment in China. "An ideal partner for us" says Torbjörn Bjerke, CEO of Orexo.
-
New member to Active board
The Election Committee of Active Biotech proposes a very experienced financial sector executive to join the company board. Five existing members are also to be ...
-
New NO product reduces diabetic pain
The Swedish medtech company Nolabs has announced that it has achieved an important milestone in the development of a new line of products.
-
Take off for this year's fair
More visitors than previously were preregistered when Scanlab and Biotech Forum opened today. But the future of the exhibitions and their design is uncertain.
-
Mathematician new dean at DTU
On January 1st the Technical University of Denmark, DTU, got a new dean, recruited from the department of Mathematics.
-
Parnevik firm in Swiss osteoporosis deal
The golf legend Jesper Parnevik's drug delivery firm EffRx has signed a license agreement with Nycomed for a new drug against osteoporosis.
-
Vitrolife köper IVF-bolag i USA
Vitrolife köper det amerikanska företaget Conception Technologies för 33,5 miljoner och breddar sin portfölj inom provrörsbefruktning.
-
Medivir tar in 280 miljoner
En riktad nyemission med B-aktier ska finansiera befintliga och kommande projekt mot infektionssjukdomar.
-
Datorn som matchmaker
Datorbaserade modeller kan användas för att förstå interaktioner mellan två läkemedel eller förutsäga biverkningar. - Det blir också möjligt att identifiera pro...
-
Symphogen buys tumor blocking technology
The seller is a pioneer in developing ligand traps to treat cancer and other diseases. "An excellent fit with our scientific and strategic focus," said Kirsten ...
-
Polymer guru new dean at DTU
The Technical University of Denmark, DTU, has appointed a well-known profile from the Polymer Center as a new dean.
-
Ny generation digitala mikroskop med många applikationer
DVM2500 och DVM5000 HD är namnen på två nya mikroskopsystem som ska kunna skräddarsys för att passa en lång rad olika applikationer.
-
Recipharm launches into biologics manufacturing
Recently a Swedish biomanufacturing facility transfers from Astrazeneca to Recipharm Biologics.
-
Biologer blir hedersdoktorer
Till vardags har de tre världsledande forskarna sin hemmabas i Tokyo, San Diego och vid Sahlgrenska Instutet. I maj blir blir de promoverade till hedersdoktorer...
-
Kancera ändrar fokus
Kancera lägger ner vaccinutvecklingen och Active Biotech, Hansa Medical, Bactiguard, Raysearch och Boule visar upp ett minskat resultat.
-
VTT in brief
VTT is a broad science cluster with research within applied materials, chemical and biochemical processes, energy, industrial systems management, information an...
-
Age essential when testing drugs
Anders Rane has been arguing that genes and age are both important factors in understanding how medicines affect individuals. Only last year, the EU established...
-
Swedish top scientists to EMBO
Two Swedish top scientists will have a really good chance to influence European life science research from now on. One is from the Karolinska Institutet, and on...
-
EUR 2 million for peanut allergies
ALK Abelló has signed an agreement to invest EUR 2 million in the French biotechnology company DBV Technologies.
BREAKING